Business
NeuroTargets Patent Grant
NeuroTargets Patent Grant.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n RNS Number : 0522Z Angle PLC 07 January 2011 \n \n\n \n \n\n\n\n\nFor immediate release\n\n\n7 January 2011\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nNeuroTargets Patent Grant \n \nANGLE plc (\"ANGLE\"), the international venture management company focusing on the commercialisation of technology and innovation, is delighted to announce further progress with NeuroTargets, its 25% portfolio company specialising in neurological conditions. ANGLE also holds convertible loans in NeuroTargets, which if converted could increase its holding to c. 70%.\n \nAs previously announced, NeuroTargets has licensed its intellectual property in relation to neuropathic pain therapeutic molecules to the University of Bristol, who have used that background IP to successfully raise funding of £4.3 million from the Wellcome Trust to advance its galanin programme focused on new treatments for neuropathic pain.\n \nIn addition to the work on neuropathic pain, NeuroTargets has through Professor Wynick's research also progressed investigation of the use of its galanin-based molecules for the treatment of Multiple Sclerosis (MS) and Alzheimer's disease (AD) and has had positive pre-clinical results. The MS work has been published in Proceedings of the National Academy of Sciences of USA and most recently Professor Wynick has submitted a scientific paper to the Journal of Alzheimer's Disease providing the scientific basis for the use of galanin to treat AD. Following peer review it is hoped that this paper will be published in early Summer 2011.\n \nNeuroTargets has submitted applications for patents over the use of galanin molecules for the treatment of MS and AD. The first such application has now resulted in a granted patent in Australia for the use of galanin to treat MS and AD. The applications in the US, EU and other important territories are ongoing.\n \n \n \nANGLE Founder and Chief Executive, Andrew Newland, commented:\n \n\"The grant of this patent extends NeuroTargets' intellectual property beyond the neuropathic pain area into the major markets for unmet clinical need of Multiple Sclerosis (MS) and Alzheimer's disease (AD).\" \n \n \n \nFor further information:\n \n\n\n\n\nANGLE plc\n\n\n01483 685830\n\n\n\n\nAndrew Newland, Ch...